Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has entered into a partnership with Shanghai-headquartered medical imaging company United Imaging Healthcare (UIH, SHA: 688271). The collaboration aims to harness the power of advanced medical intelligent technologies to enhance medical services.
Integrating AI and Nuclear Medicine into Diagnostic Services
Under this strategic alliance, Hybribio will integrate UIH’s artificial intelligence software and hardware technology platform, the UIH intelligent medical platform, and the joint nuclear platform of nuclear medicine science and technology. This integration will accelerate the establishment of a medical equipment interconnection platform, which is expected to significantly improve Hybribio’s intelligent management and operational capabilities.
Enhancing Diagnostic and Treatment Capabilities
The partnership will also bolster Hybribio’s discipline diagnosis and treatment abilities, technical level, medical quality, and talent quality. The collaboration will lead to in-depth cooperation across various aspects, ensuring that Hybribio remains at the forefront of medical diagnostic technology and services. No financial details of the partnership have been disclosed, indicating the focus is on the strategic and technological synergy rather than immediate financial gains.-Fineline Info & Tech
